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A B S T R A C T
We describe the case of a 61-year-old Japanese woman who developed acute heart failure 5 years after
chemoradiotherapy for breast cancer. The patient received less than the cardiotoxic dose of docetaxel,
epirubicin, cyclophosphamide, and ﬂuorouracil and experienced no cardiovascular complications in the
5 years between the onset of chemoradiotherapy and the onset of acute heart failure. Cardiac
catheterization was performed and elevation of end diastolic pressure of both ventricles was observed.
Endomyocardial biopsy showed progressive replacement ﬁbrosis in the subendocardium. Normal
thickness of the right endocardium is <20 mm. Surprisingly, our patient had a ﬁbrous subendocardium
that was 100–200 mm thick. Ultrastructural abnormalities similar to those observed in anthracycline
cardiotoxicity were evident on electron micrographs. This case report demonstrates the unique
pathophysiology of heart failure in a patient who received less than the cardiotoxic dose of
antineoplastic agents. Recent protocols have decreased the dosage of cardiotoxic agents; however, even
these reduced doses might not be safe for all Japanese individuals and may cause subclinical
cardiovascular damage and late-onset heart failure. Clinicians shouldmonitor cancer survivors carefully,
even if antineoplastic agents were administered under the cardiotoxic dose.
<Learning objective: Intensive chemotherapy is commonly used to treat cancer patients. Recent
protocols have decreased the dose of cardiotoxic agents; however, even these reduced doses might not
be safe and may cause subclinical cardiovascular damage and late-onset heart failure. Clinicians should
monitor cancer survivors carefully, even if antineoplastic agents were administered under the toxic
dose.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
In Japan, the incidence of breast cancer has increased in recent
years, but the survival of patients with newly diagnosed breast
cancer has improved [1]. With advancements in chemotherapy
regimens, mortality rates are decreasing by 2.3% annually [2], and
the 5-year survival rate for advanced breast cancer has increased to
30% [3]. In the past, cardiovascular complications were rare in
breast cancer patients because the lifespan of a patient with
advanced cancer was too short for the issue to manifest. However,
more recent reports indicate that there are now a considerable* Corresponding author at: Chu-o-ku Kawagishicho 2-15-3, Niigata City
951-8560, Japan. Tel.: +81 25 266 5111; fax: +81 25 378 8986.
E-mail address: okuray@niigata-cc.jp (Y. Okura).
http://dx.doi.org/10.1016/j.jccase.2014.06.002
1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsnumber of cancer survivors who develop chemotherapy-related
cardiac dysfunction and thus are under periodic observation by a
cardiologist [4]. Here we describe a breast cancer patient who
developed acute heart failure (HF) 5 years after chemoradiother-
apy. We observed unique subendocardial ﬁbrosis in the endo-
myocardial biopsy despite the fact that all antineoplastic agents
had been delivered under the cardiotoxic dose.
Case report
A61-year-old Japanesewoman experienced shortness of breath
inMay 2012, 5 years after she had undergone a partial mastectomy
and received subsequent chemoradiotherapy for breast cancer.
Threeweeks later, she developed dyspnea, general fatigue, and loss
of appetite, and she was therefore admitted to our hospital with
orthopnea. A chest radiograph revealed cardiomegaly, pulmonaryreserved.
D. Yuki et al. / Journal of Cardiology Cases 10 (2014) 115–120116congestion, and bilateral pleural effusion. At the time of hospital
admission, the patient’s weight had increased by 5 kg since her last
regular medical check-up 4 weeks earlier. Physical examination
showed moist rale in bilateral lower lung ﬁelds, and the patient
was diagnosed with acute pulmonary edema.[(Fig._1)TD$FIG]
Fig. 1.
Electrocardiograms before chemotherapy (October, 2006) (A), after chemothe
2012) (C), and 6 months later (November, 2012) (D) (10 mm/mV). Slight and n
signiﬁcant differences. Electrocardiogram at the time of heart failure admiss
segment depression associated with T-wave inversion in V5,6 (C). Six months
depression remained in II, III, aVF, V5,6 (D).The patient had been diagnosed with right breast cancer
without metastasis in October 2006. The tumor was 5.3 cm in size
and located in the lower medial region of the right chest (T3N1M0,
stage IIIa). Initial chemotherapy with docetaxel (cumulative dose,
300 mg/m2) proved ineffective. After cardiovascular screening, sherapy (April, 2007) (B), at the time of hospital admission due to heart failure (May,
on-speciﬁc ST segment depression was observed in (A) and (B), but there were no
ion showed diminished QRS amplitude, poor R waves in precordial leads, and ST
later, the QRS amplitude almost normalized in precordial leads, but ST segment
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with cyclophosphamide and ﬂuorouracil (cumulative dose,
2000 mg/m2 for each) from February to April 2007. She underwent
a partial mastectomy in May 2007, followed by whole-breast
irradiation of 60 Gy. The patient did not display any clinical[(Fig._2)TD$FIG]
Fig. 2.
Histopathological and immunohistochemical ﬁndings from the endomyocard
at the location indicated by the asterisk is 100 mm (hematoxylin–eosin stainin
the ﬁbrous subendocardium (arrow). Smoothmuscle cells were also observed
Mallory stain, original magniﬁcation 200). (C) Subendocardial thickness reac
red-violet-stained single layer (asterisk). The shape of myocytes appeared inta
anti-desmin stain (Dako), but myocytes in the subendocardial ﬁbrotic tissuesymptoms of HF during chemoradiotherapy. Echocardiography
showed normal left ventricular (LV) size and LV ejection fraction
(LVEF; 5.2 cm and 70%, respectively). After these therapies, the
concentration of the tumor markers CEA and CA15-3 decreased
and then remained within their normal ranges.ial biopsy. (A) Subendocardial thickening was observed. Subendocardial thickness
g, original magniﬁcation 200). (B) Some degenerated myocytes were observed in
in the subendocardium. Neither interstitial ﬁbrosis nor edemawas observed (Azan
hed 200 mm around somemyocytes (arrows). The endotheliumwas observed as a
ct (Gitter stain, original magniﬁcation 200). (D) Most myocytes were positive for
(arrows) were relatively less stained (original magniﬁcation 200).
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showed poor R-wave progression and ST depression with inverted
T in precordial leads (Fig. 1C). N-terminal pro-B-type natriuretic
peptide was elevated, at 4684 pg/mL. A test for serum troponin T
(Elecsys1 troponin T STAT test; Roche, Basel, Switzerland) was
negative, and creatine kinase level was normal. Echocardiography
revealed a dilated and diffusely hypokinetic LV (LV size 6.3 cm and
LVEF 34%).
The patient was diagnosed with acute cardiogenic pulmonary
edema and was administered oxygen, diuretics (40 mg/d of
furosemide), and vasodilators (10 mg/d of nitroglycerin and
2.5 mg/d of enalapril). She recovered from dyspnea, and cardiac
catheterization was performed on day 9 after hospital admission.
Mean pulmonary artery wedge pressure, pulmonary artery
pressure, and cardiac index were normalized at 13 mmHg,
20 mmHg, and 3.2 L/min/m2, respectively. However, end-diastolic
pressure was elevated in the right and left ventricles (13 and
20 mmHg, respectively). Dip and plateau pattern of ventricular
diastolic pressure was not observed. Left ventriculography
indicated a dilated LV (131 mL/m2 of end diastolic volume index)
with diffuse hypokinesis (LVEF 27%). Coronary arteries were
normal. Endomyocardial biopsy from the right ventricle showed an
extremely thickened subendocardium (100–200 mm thick) with
replacement ﬁbrosis, and some smooth muscle cells and degen-
erated myocytes were surrounded by collagen ﬁbers (Fig. 2). There
was a small amount of interstitial ﬁbrosis and inﬁltration of
mononuclear cells. Although myocytes appeared intact under a
light microscope, injury to the ultrastructure of myocytes was
evident in electron micrographs (Fig. 3).
On day 12 after hospital admission, the patient was examined
using myocardial single-photon emission computed tomography
(SPECT) with 201Tl and 123I-b-methyl-iodophenyl-pentadecanoic
acid (BMIPP) (Fig. 4A). Distribution of 201Tl and 123I-BMIPP was
patchy and independent of coronary perfusion across the whole
heart. Quantitative gated SPECT of the LV showed diffuse
hypokinesis with LVEF of 30% (Fig. 4B).
The patient gradually recovered and was discharged on day 16
after hospital admission. Six months later, LV size had normalized,
[(Fig._3)TD$FIG]
Fig. 3.
Electron micrograph of the endomyocardial biopsy. Myoﬁbrillar disruption an
Some of the mitochondria appear swollen with loss of compact cristae.and LVEF had recovered to 47% in echocardiography, but ST
segment depression remained in II, III, aVF, V5,6 in electrocardio-
gram (Fig. 1D). Although she needed diuretics and vasodilators for
peripheral edema and pulmonary edema, she regained her social
and familial activities.
Discussion
Despite receiving non-toxic doses of antineoplastic agents, our
patient developed HF with progressive subendocardial ﬁbrosis 5
years after the start of treatment for breast cancer. Normal
thickness of the right endocardium is <20mm [5], but our patient
had a ﬁbrous subendocardium that was 100–200mm thick.
Mortensen et al. [5] reported that 10 of the 11 patients with
anthracycline-associated cardiotoxicity had subendocardial ﬁbro-
sis, and themean subendocardial thickness of the right ventricle in
these 10 patients was 48 mm; hence, the subendocardial thickness
in our patient surpassed that of the most severe case in the
Mortensen et al. study, which was 60–100 mm in a 55-year-old
woman with breast cancer who was treated with doxorubicin
(575 mg/m2), cyclophosphamide, and irradiation, and died sud-
denly. Our case was treated with a modest amount of epirubicin,
which was less toxic; therefore, the severity of subendocardial
ﬁbrosis in our patient was surprising.
In addition to subendocardial ﬁbrosis, ultrastructural abnor-
malities similar to those of anthracycline cardiotoxicity were also
observed in electron micrographs. However, the doses of
chemotherapeutic agents that our patient had received were
considerably lower than the cardiotoxic doses [6]. Docetaxel was
stopped at 300 mg/m2 because of poor response. In a trial using
450 mg/m2 of docetaxel in combination with doxorubicin and
cyclophosphamide, only 1.6% of the patients developed congestive
HF in 5 years [7]. Our patient also received 240 mg/m2 of epirubicin
in combination with 2000 mg/m2 cyclophosphamide and ﬂuoro-
uracil. Ryberg et al. [8] reported that the risk of HF was
approximately 5% for a group of 60-year-old female breast cancer
patients who had been treated with 700 mg/m2 epirubicin. The
dose received by our patient was much lower than this dose.d loss, different sized clusters of mitochondria, and distorted Z-bands are evident.
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Fig. 4.
Dual single-photon emission computed tomography (SPECT) with 201Tl and 123I-b-methyl-iodophenyl-pentadecanoic acid (123I-BMIPP) on day 12 after hospital
admission. (A) Myocardial uptake of 201Tl and 123I-BMIPP was similar across the whole heart. Uptake was almost normal, but patches of slightly lower uptake
were present, located independent of coronary perfusion. (B) A three-dimensional surface-rendered image of the left ventricle created by electrocardiogram-
gated SPECT perfusion images. The greenmesh represents the endocardium at end diastole, and the violet surface represents the endocardium at end systole. Left
ventricular ejection fraction (LVEF) was quantiﬁed based on the volume change. ANT, anterior region; LAT, lateral region; SEPT, septal region.
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120–170 mg/kg [4], and our patient had received only one-third of
the lower limit of this range.
The potential adverse effects of whole-breast irradiation should
also be considered for our patient. She received 60 Gy of irradiation
near the right heart 5 years prior to the onset of acute cardiogenic
pulmonary edema. Radiation-induced damage to the heart and/or
vasculature increases the subsequent rate of ischemic heart
disease [9]. Recently, Darby et al. [10] reported that incidental
exposure of the heart to radiotherapy for breast cancer increased
the rate of major coronary events (myocardial infarction, coronary
revascularization, or death from ischemic heart disease) by 7.4%
per Gy, with no apparent threshold, and the increase startedwithin
5 years of radiotherapy. For our patient, the combination of
chemotherapy and radiotherapy was clearly effective for treating
her cancer, but may have adversely affected her heart.There are several possible reasons for the severe injury to the
subendocardium as presented by our patient. First, perfusion of
chemotherapeutic agents into the subendocardium through the
endocardium during chemotherapy might have negatively impact-
ed adjacent myocytes. Second, compared with the epicardium, the
subendocardium is more vulnerable to various stressors including
ischemia, tachycardia, excessive preload, and cardiotoxicity. Al-
though coronary arteriography of our patient appeared normal at
the epicardium, the subendocardial microvasculature might have
been injured by antineoplastic agents and radiation. We speculate
that the combination of chemotherapy and radiotherapy may
synergisticallyamplify their cardiotoxicities and inﬂict local damage
on the most vulnerable region of heart, i.e. the subendocardium.
The incidence of breast cancer is increasing in Japan [1].
Chemotherapy is believed to be safe because improved protocols
avoid high doses of cardiotoxic agents by combining them with
D. Yuki et al. / Journal of Cardiology Cases 10 (2014) 115–120120antineoplastic agents. However, the cardiotoxic threshold doses of
these agents in Japanese individuals remain uncertain becausemost
clinical trials of breast cancer have been performed in the USA and
have included few patients of Japanese ethnicity. Recent protocols
might not be safe for ethnic Japanese individuals and may cause
subclinical cardiovascular damage and late-onset HF. Therefore,
clinicians should monitor cancer survivors carefully, even if all
antineoplastic agents were administered under the toxic level. We
recommend that all survivors have an annual check-up with
electrocardiogram and chest radiograph for HF screening. Breast
surgeons and cardiovascular specialists should work together for
early detection of asymptomatic patients with LV dysfunction.
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